It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Seipin is one key mediator of lipid metabolism that is highly expressed in adipose tissues as well as in the brain. Lack of Seipin gene, Bscl2, leads to not only severe lipid metabolic disorders but also cognitive impairments and motor disabilities. Myelin, composed mainly of lipids, facilitates nerve transmission and is important for motor coordination and learning. Whether Seipin deficiency-leaded defects in learning and motor coordination is underlined by lipid dysregulation and its consequent myelin abnormalities remains to be elucidated. In the present study, we verified the expression of Seipin in oligodendrocytes (OLs) and their precursors, oligodendrocyte precursor cells (OPCs), and demonstrated that Seipin deficiency compromised OPC differentiation, which led to decreased OL numbers, myelin protein, myelinated fiber proportion and thickness of myelin. Deficiency of Seipin resulted in impaired spatial cognition and motor coordination in mice. Mechanistically, Seipin deficiency suppressed sphingolipid metabolism-related genes in OPCs and caused morphological abnormalities in lipid droplets (LDs), which markedly impeded OPC differentiation. Importantly, rosiglitazone, one agonist of PPAR-gamma, substantially restored phenotypes resulting from Seipin deficiency, such as aberrant LDs, reduced sphingolipids, obstructed OPC differentiation, and neurobehavioral defects. Collectively, the present study elucidated how Seipin deficiency-induced lipid dysregulation leads to neurobehavioral deficits via impairing myelination, which may pave the way for developing novel intervention strategy for treating metabolism-involved neurological disorders.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Shanxi Medical University, School of Basic Medical Sciences, Taiyuan, China (GRID:grid.263452.4) (ISNI:0000 0004 1798 4018); Shanxi Medical University, Key Laboratory of Cellular Physiology, Ministry of Education, Taiyuan, China (GRID:grid.263452.4) (ISNI:0000 0004 1798 4018)
2 Shanxi Medical University, School of Basic Medical Sciences, Taiyuan, China (GRID:grid.263452.4) (ISNI:0000 0004 1798 4018)
3 Chinese Academy of Sciences, Analytical Instrumentation Center & State Key Laboratory of Coal Conversion, Institute of Coal Chemistry, Taiyuan, China (GRID:grid.9227.e) (ISNI:0000000119573309)
4 Chinese Academy of Sciences, Center of Medical Physics and Technology, Hefei Institutes of Physical Science, Hefei, China (GRID:grid.9227.e) (ISNI:0000000119573309)
5 Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore, Singapore (GRID:grid.59025.3b) (ISNI:0000 0001 2224 0361)
6 Soochow University, Jiangsu Key Laboratory of Neuropsychiatric Diseases, Institute of Neuroscience, Suzhou, China (GRID:grid.263761.7) (ISNI:0000 0001 0198 0694)